STOCK TITAN

Centessa Pharmaceuticals plc - CNTA STOCK NEWS

Welcome to our dedicated news page for Centessa Pharmaceuticals plc (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Centessa Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Centessa Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announces the presentation of additional 52-week data from the ongoing Phase 2a study of SerpinPC for hemophilia treatment at EAHAD Congress. SerpinPC shows promise as a novel inhibitor of activated protein C, with positive results reinforcing its potential as a convenient subcutaneous treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.13%
Tags
conferences clinical trial
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced its participation in upcoming investor conferences, including Guggenheim’s 6th Annual Biotechnology Conference and Leerink Partners Global Biopharma Conference 2024. The live webcasts and archived recordings will be available on the company's investor relations section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Saurabh Saha MD PhD, CEO, to present on January 10, 2024, at 4:30 PM PST. The event will be available for live audio webcast and archived recording on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) presented additional data from the third year of the Phase 2a study of SerpinPC for the treatment of hemophilia at the American Society of Hematology (ASH) Annual Meeting. The data showed a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline, reinforcing the favorable safety and tolerability profile of SerpinPC. No thromboembolic events or treatment-related sustained elevations of D-dimer were observed during the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA): Ongoing studies for hemophilia B treatment, new data at ASH Annual Meeting, preclinical data on narcolepsy treatment presented at World Sleep Congress, financial results and business highlights for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
earnings
-
Rhea-AI Summary
Centessa Pharmaceuticals announced that new data from the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia will be presented at the 65th ASH Annual Meeting. SerpinPC is an investigational inhibitor of activated protein C in registrational studies for hemophilia B. The Phase 2a study is investigating the safety, tolerability, pharmacokinetics, and efficacy of SerpinPC in male participants with severe hemophilia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Summary
Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The study is a Phase 2b, global, open-label study to investigate the efficacy and safety of subcutaneous dosing of SerpinPC. The primary efficacy endpoint is the rate of treated bleeds compared to the first 24 weeks of treatment with SerpinPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that its management team will participate in two upcoming investor conferences: Jefferies London Healthcare Conference on November 15, 2023, in London, and Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023, in Miami, FL. Access to live webcasts and archived recordings will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
conferences
-
Rhea-AI Summary
Centessa Pharmaceuticals announces new preclinical data on ORX750, a potential treatment for narcolepsy and sleep-wake disorders. The data show significant activity at low doses of ORX750 in translational models of narcolepsy type 1 (NT1) and other sleep-wake disorders. Clinical proof of concept data is planned for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
clinical trial
Rhea-AI Summary
Centessa Pharmaceuticals announces the appointment of April Dovholuk and Ellie Im to its executive team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
Centessa Pharmaceuticals plc

Nasdaq:CNTA

CNTA Rankings

CNTA Stock Data

1.04B
40.33M
2.01%
86.31%
1.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Altrincham

About CNTA

centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.